当前位置： SCI文献检索 > Drug Metabolism and Pharmacokinetics期刊下所有文献 > Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.

Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.

Abstract：

:Dihydrofolate reductase gene (DHFR) 19-bp deletion polymorphisms result in varied DHFR enzymatic activity affecting the risk for preterm delivery, spina bifida, and the efficacy of methotrexate (MTX). Ethnic differences in DHFR 19-bp polymorphisms may be responsible for the divergent findings in previous genetic studies. We compared genotype and allele frequency of DHFR intronic 19-bp deletion polymorphisms in ethnically homogenous East Asians (from Japan) and others by polymerase chain reaction assay conducted on 277 healthy Japanese individuals. The genotype distribution was as follows: wild/wild, 11.9% (n=33); wild/deletion, 40.1% (n=111); deletion/deletion, 48.0% (n=133). The frequencies of wild type and deletion alleles were 0.32 and 0.68, respectively. The obtained genotype distribution was consistent with those calculated by Hardy-Weinberg equilibrium. The genotype distribution and allele frequencies in the Japanese population were significantly different from those previously reported for other ethnic populations. Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.

journal_name

Drug Metab Pharmacokinet

journal_title

Drug metabolism and pharmacokinetics

authors

Hayashi H,Horino M,Morishita M,Tazoe Y,Tsuboi S,Matsuyama T,Kosuge K,Yamada H,Tsuji D,Inoue K,Itoh K

doi

10.2133/dmpk.dmpk-10-sc-036

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

516-8

issue

5

eissn

1347-4367

issn

1880-0920

pii

JST.JSTAGE/dmpk/DMPK-10-SC-036

journal_volume

25

pub_type

杂志文章

相关文献

Drug Metabolism and Pharmacokinetics文献大全
  • Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters.

    abstract：:To characterize the renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem in humans, we examined their affinities as substrates to human renal transporters. In vitro studies on the uptake of [14C]CS-023 and [14C]meropenem were conducted using HEK293 cells expressing human organi...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.22.41

    authors： Shibayama T,Sugiyama D,Kamiyama E,Tokui T,Hirota T,Ikeda T

    更新日期：2007-02-25 00:00:00

  • Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels.

    abstract：:CYP2D6 is involved in the biotransformation of a large number of drugs, including risperidone. This study was designed to detect CYP2D6 polymorphisms with a Luminex assay, including assessment the relationship of CYP2D6 polymorphisms and risperidone plasma concentration in autism spectrum disorder children (ASD) treat...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2016.01.005

    authors： Vanwong N,Ngamsamut N,Hongkaew Y,Nuntamool N,Puangpetch A,Chamnanphon M,Sinrachatanant A,Limsila P,Sukasem C

    更新日期：2016-04-01 00:00:00

  • Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.

    abstract：:In this study, we aimed to understand the gap in coverage of pharmacogenomic (PGx) biomarkers between Japan and the US. PGx biomarkers (1) in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; (2) that are CPIC level A or B; or (3) have US Food and Drug Administration (FDA)-approved drug labels...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2018.08.006

    authors： Hikino K,Fukunaga K,Mushiroda T

    更新日期：2018-12-01 00:00:00

  • Lack of a primary physicochemical determinant in the direct transport of drugs to the brain after nasal administration in rats: potential involvement of transporters in the pathway.

    abstract：:The objectives of this study were to evaluate the relative contribution of the direct pathway in overall brain transport for 17 model drugs with different physicochemical properties after nasal administrations and to identify factors that govern the fraction of the dose transported to the brain via the direct pathway ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-10-rg-049

    authors： Lee KR,Maeng HJ,Chae JB,Chong S,Kim DD,Shim CK,Chung SJ

    更新日期：2010-01-01 00:00:00

  • A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.

    abstract：:A novel method for the prediction of drug-drug interaction has been established based on the in vitro metabolic stability in the "serum incubation method" using cryopreserved human hepatocytes suspended in 100% human serum. As a novel approach, the inhibitory effect of inhibitors on the metabolism of substrates during...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.23.328

    authors： Shibata Y,Takahashi H,Chiba M,Ishii Y

    更新日期：2008-01-01 00:00:00

  • Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

    abstract：:Analysis of mRNAs from liver biopsy samples of patients with chronic hepatitis C revealed that the levels of nuclear receptor expression were correlated with those of drug-metabolizing enzymes and transporters in relation to the development of fibrosis. Overall, the median mRNA level was largely dependent on fibrosis ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-11-rg-077

    authors： Hanada K,Nakai K,Tanaka H,Suzuki F,Kumada H,Ohno Y,Ozawa S,Ogata H

    更新日期：2012-01-01 00:00:00

  • Bonitos with low content of malodorous trimethylamine as palliative care for self-reported Japanese trimethylaminuria subjects.

    abstract：:Trimethylaminuria is caused by excessive malodorous trimethylamine excreted via urine and body secretion by decreased hepatic flavin-containing monooxygenase 3 (FMO3) metabolic capacity for transforming non-odorous trimethylamine N-oxide. This study investigates foodstuff first in healthy volunteers for palliative car...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.24.549

    authors： Shimizu M,Kozono M,Murayama N,Yamazaki H

    更新日期：2009-01-01 00:00:00

  • Effect of protein binding of pilsicainide on the pharmacokinetics.

    abstract：:To evaluate the effect of protein binding of pilsicainide on its clearance and the contribution of protein binding to optimized pilsicainide therapy, clinical laboratory and pharmacokinetic data were studied in 160 Japanese inpatients (Study 1) and 18 Japanese inpatients (Study 2). To determine the relation between pr...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.20.183

    authors： Fukumoto K,Tanemura M,Tsuchishita Y,Kusumoto M,Matsumoto K,Kamakura S,Ueno K

    更新日期：2005-06-01 00:00:00

  • Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis.

    abstract：:The aim of this study was to investigate the impact of genetic polymorphisms in the metabolic and cellular transport pathway of methotrexate (MTX) on the clinical outcome of MTX monotherapy in Japanese rheumatoid arthritis (RA) patients. Fifty-five patients were treated with MTX monotherapy at a dose of 4-10 mg/week. ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-11-rg-066

    authors： Kato T,Hamada A,Mori S,Saito H

    更新日期：2012-01-01 00:00:00

  • Estimation of in vivo percutaneous absorption of emedastine from bile excretion data using a deconvolution method.

    abstract：:In vivo percutaneous absorption of emedastine difumarate was investigated in rats and compared with rat skin in vitro. Since emedastine entering the systemic circulation is mostly excreted in bile, we first came up with the method of collecting bile with a minimal skin incision. In vivo skin permeation of the drug was...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.20.331

    authors： Harada S,Yamashita F,Hashida M

    更新日期：2005-10-01 00:00:00

  • Post-transcriptional regulation of OATP2B1 transporter by a microRNA, miR-24.

    abstract：:Human OATP2B1, a member of organic anion transporting polypeptide family, is expressed in several tissues, including small intestine and liver, and contributes to cellular uptake of endogenous compounds and various drugs. Altered expression of OATP2B1 affects pharmacokinetics of substrate drugs; however, limited infor...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2020.07.007

    authors： Liu W,Nakano M,Nakanishi T,Nakajima M,Tamai I

    更新日期：2020-12-01 00:00:00

  • Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.

    abstract：:Pitavastatin undergoes little hepatic metabolism but it is a substrate for uptake and efflux transporters, particularly OATP1B1 (gene SLCO1B1). A previous study in 8 Japanese healthy subjects showed that co-administration with grapefruit juice (GFJ) resulted in a small increase in systemic exposure to pitavastatin. We...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,随机对照试验

    doi：10.2133/dmpk.dmpk-12-rg-067

    authors： Hu M,Mak VW,Yin OQ,Chu TT,Tomlinson B

    更新日期：2013-01-01 00:00:00

  • Metabolic extraction of nifedipine during absorption from the rat small intestine.

    abstract：:Nifedipine is one of drugs that have been suggested to undergo significant first-pass metabolism by cytochrome P450 (CYP) 3A in the intestine, based mainly on pharmacokinetic analyses of in vivo observations. To further substantiate this suggestion, we examined the metabolic extraction of nifedipine from the rat small...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.17.546

    authors： Iwao T,Inoue K,Hayashi Y,Yuasa H,Watanabe J

    更新日期：2002-01-01 00:00:00

  • Enhanced uptake of glycerol by butyrate treatment in HCT-15 human colon cancer cell line.

    abstract：:The HCT-15 human colon cancer cell line has a Na(+)-dependent carrier-mediated transport system for the uptake of glycerol. A similar transport system has been suggested to be present also in the small intestine and is of interest with regard to its role in the absorption of glycerol and possibly some structurally rel...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.22.195

    authors： Fujimoto N,Inoue K,Ohgusu Y,Hayashi Y,Yuasa H

    更新日期：2007-06-01 00:00:00

  • Decreased expression of intestinal P-glycoprotein increases the analgesic effects of oral morphine in a streptozotocin-induced diabetic mouse model.

    abstract：:Morphine is one of the strongest analgesics and is commonly used for the treatment of chronic pain. The pharmacokinetic properties of morphine are, in part, modulated by P-glycoprotein (P-gp). We previously reported that intestinal P-gp expression levels are influenced via the activation of inducible nitric oxide synt...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-11-rg-051

    authors： Nawa A,Fujita-Hamabe W,Kishioka S,Tokuyama S

    更新日期：2011-01-01 00:00:00

  • Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.

    abstract：:Resistance to antiemetic treatment with 5-hydroxytryptamine 3 receptor antagonists is a problem, with 20-30% of patients showing unsatisfactory responses. Efflux transport by P-glycoprotein, encoded by the ATP-binding cassette ABCB1 gene in the blood-brain barrier, has been the suggested resistance mechanism. We evalu...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-12-rg-084

    authors： Tsuji D,Kim YI,Nakamichi H,Daimon T,Suwa K,Iwabe Y,Hayashi H,Inoue K,Yoshida M,Itoh K

    更新日期：2013-01-01 00:00:00

  • Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2.

    abstract：:Genetic polymorphisms in xenobiotic transporters have recently been clarified to be associated with change in drug distribution and disposition. To expand on recent identification of direct interaction and functional regulation of several transporters by a PDZ (PSD95, Dlg and ZO1) domain containing protein PDZK1, the ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.21.375

    authors： Sugiura T,Kato Y,Kubo Y,Tsuji A

    更新日期：2006-10-01 00:00:00

  • Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect.

    abstract：:DDI could be caused by the inhibition of OATP-mediated hepatic uptakes. The aim of this study is to set the risk criteria for the compounds that would cause DDI via OATP inhibition at the drug discovery stage. The IC50 values of OATP inhibitors for human OATP-mediated atorvastatin uptake were evaluated in the expressi...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2016.05.003

    authors： Nakakariya M,Goto A,Amano N

    更新日期：2016-10-01 00:00:00

  • Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.

    abstract：:A population pharmacokinetic (PK) model for meropenem in Japanese pediatric patients with various infectious diseases was developed based on 116 plasma concentrations from 50 pediatric patients. The population PK parameters developed in this analysis are useful for calculation of the percent time above minimum inhibit...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-11-rg-027

    authors： Ohata Y,Tomita Y,Nakayama M,Kozuki T,Sunakawa K,Tanigawara Y

    更新日期：2011-01-01 00:00:00

  • Safety evaluation and drug development based on biological fate of drugs -efforts made to overcome drug interaction in drug development-.

    abstract：:1. Assay methods to detect drug interaction in toxicological samples were established by determining cytochrome P450 content and its activity in liver samples. The O-dealkylation reaction of 7-alkoxycoumarin was indicated to reflect changes in the molecular forms of P450s, and the enzyme induction or inhibition in the...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.17.379

    authors： Matsubara T

    更新日期：2002-01-01 00:00:00

  • The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects.

    abstract：:Cytochrome P450 (CYP) 3A-related drug-drug interaction (DDI) studies are needed during drug development to determine clinical interaction effects. We aimed to evaluate DDI between sildenafil and two CYP3A inhibitors, clarithromycin and itraconazole, regarding the changes in pharmacokinetics and endogenous markers. An ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2020.11.003

    authors： Lee S,Kim AH,Yoon S,Lee J,Lee Y,Ji SC,Yoon SH,Lee S,Yu KS,Jang IJ,Cho JY

    更新日期：2021-02-01 00:00:00

  • Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.

    abstract：:The objectives of this study were to develop a population pharmacokinetic model of imidafenacin and to explore the factors that affect the pharmacokinetics of imidafenecin. A total of 2406 plasma samples were collected from 90 healthy volunteers and 457 patients with overactive bladder. We determined the plasma concen...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.23.456

    authors： Ohno T,Nakade S,Nakayama K,Kitagawa J,Miyabe H,Konomi T,Miyata Y

    更新日期：2008-01-01 00:00:00

  • The regulation mechanism of AhR activated by benzo[a]pyrene for CYP expression are different between 2D and 3D culture of human lung cancer cells.

    abstract：:Most of cytochrome P450 (CYP) expressions are regulated by nuclear receptors. The regulation pathways of transcription are activated by binding of the ligand to the receptor. Many combination of CYPs and nuclear receptors in transcriptional regulation have been reported. However, we have reported that the combination ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2018.04.002

    authors： Terashima J,Jimma Y,Jimma K,Hakata S,Yachi M,Habano W,Ozawa S

    更新日期：2018-08-01 00:00:00

  • Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents.

    abstract：:  Human cytochrome P450 CYP2A6 and CYP2A13 catalyze nicotine metabolisms and mediate activation of tobacco-specific carcinogens including 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). In this study, we found rhinacanthins A, B, and C isolated from Rhinac...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-13-rg-048

    authors： Pouyfung P,Prasopthum A,Sarapusit S,Srisook E,Rongnoparut P

    更新日期：2014-01-01 00:00:00

  • Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3).

    abstract：:Polymorphic human and cynomolgus macaque flavin-containing monooxygenases (FMO) 3 are important oxygenation enzymes for nitrogen-containing drugs. Inter-animal variability of FMO3-dependent drug oxygenations in vivo is suspected in cynomolgus macaques because such variability is evident in humans. Therefore, this foll...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2020.07.001

    authors： Shimizu M,Uno Y,Utoh M,Yamazaki H

    更新日期：2020-12-01 00:00:00

  • Genetic variations in the MCT1 (SLC16A1) gene in the Chinese population of Singapore.

    abstract：:MCT1(SLC16A1) is the first member of the monocarboxylate transporter (MCT) and its family is involved in the transportation of metabolically important monocarboxylates such as lactate, pyruvate, acetate and ketone bodies. This study identifies genetic variations in SLC16A1 in the ethnic Chinese group of the Singaporea...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.24.469

    authors： Lean CB,Lee EJ

    更新日期：2009-01-01 00:00:00

  • Decrease in ciprofloxacin absorption by polyvalent metal cations is not fully attributable to chelation or adsorption.

    abstract：:The drug interaction between new quinolone antibiotics (NQs) and polyvalent metal cation products, leading to a significant decrease in the absorption of NQ, is considered to be attributable to the formation of poorly absorbable chelate and physicochemical adsorption of NQs to cation products. To clarify the mechanism...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-14-rg-001

    authors： Imaoka A,Hattori M,Akiyoshi T,Ohtani H

    更新日期：2014-01-01 00:00:00

  • Identification of primary equilibrative nucleoside transporter 1 mRNA isoforms resulting from alternative promoter usage in human hepatocytes.

    abstract：:Human equilibrative nucleoside transporter 1 (hENT1) transports various nucleoside analogues into cells. Although the single hENT1 promoter region (P1) and the mRNA isoform (a1) have been characterized previously, we have recently identified additional promoter regions P2 and P3 (which primarily generate c1/2/3 mRNAs ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-13-rg-135

    authors： Furihata T,Mizuguchi M,Suzuki Y,Matsumoto S,Kobayashi K,Chiba K

    更新日期：2014-01-01 00:00:00

  • Population pharmacokinetics of valsartan in pediatrics.

    abstract：:The objective of this work was to develop a population pharmacokinetic model to assess the influence of subject covariates on the pharmacokinetics of valsartan in children. Data were collected from a single dose study in 26 hypertensive children ages 1 to 16 years. Subjects received 2 mg/kg valsartan suspension up to ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,多中心研究

    doi：10.2133/dmpk.24.145

    authors： Habtemariam B,Sallas W,Sunkara G,Kern S,Jarugula V,Pillai G

    更新日期：2009-01-01 00:00:00

  • The population genetics of pharmacogenomics VIP variants in the Sherpa population.

    abstract：:Polymorphic distributions of pharmacogenes among some ethnicities are under-represented in current pharmacogenetic research. Particularly, there is a paucity of pharmacogenetic information in the Sherpa population in Tibet. We used the Sequenom MassARRAY single nucleotide polymorphism (SNP) genotyping technology to de...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.11.007

    authors： Wang L,Ren Y,Shi X,Yuan D,Liu K,Geng T,Li G,Kang L,Jin TB

    更新日期：2016-02-01 00:00:00